SAC Meeting Calendar
Newest Background Analyses
Search by Tag
- AAC
- AADPAC
- ACHDNC
- ACPS-CP
- AIDAC
- alogliptin
- AMDAC
- Amgen
- ankylosing spondylitis
- anti-hypertensives
- antibacterial
- APAC
- asthma
- AstraZeneca
- biosimilar
- bladder cancer
- blood donation
- Boehringer Ingelheim
- BPAC
- BRUDAC
- cancer
- Celltrion
- CFTR potentiator
- CLIAC
- CRDAC
- Crohn's disease
- CT-P13
- CTGTAC
- Cystic Fibrosis
- cytolitic
- diabetes
- DODAC
- DSRM
- Duchenne muscular dystrophy
- Eli Lilly
- EMDAC
- epidural steroid injections
- eteplirsen
- ezetimibe
- FDA
- GlaxoSmithKline
- HHS
- high cholesterol
- hypoactive sexual desire disorder
- infection
- infliximab
- influenza
- invasive aspergillosis
- iron deficiency
- ivacaftor
- liraglutide
- major depressive disorder
- melanoma
- Merck
- MIDAC
- monoclononal antibodies
- NDAC
- necitumumab
- neutropenia
- Novartis
- Novo Nordisk
- ODAC
- oncolytics
- opioid
- PADAC
- pain
- panobinostat
- Parkinsons disease
- PCAC
- PCNS
- PCSK9 inhibitor
- PDAC
- PEDAC
- pediatric
- pediatric anesthesia
- Pfizer
- Psoriasis
- psoriatic arthritis
- Purdue Pharma
- RCAC
- reduce CV risk
- reversal of neuromuscular blockade
- RO5503781
- Rockwell Medical
- SACHRP
- Sandoz
- Sanofi Aventis
- Sarepta Therapeutics
- SBFDA
- sugammadex
- Takeda
- talimogene laherparepvec
- testosterone
- testosterone replacement therapy
- Teva
- The Medicines Company
- TSEAC
- vaccines
- Vertex Pharmaceuticals
- VRBPAC
Pexidartinib capsule by Daiichi Sankyo, Inc., proposed for the treatment of adult patients with symptomatic tenosynovial giant cell tumor
Quizartinib tablets by Daiichi Sankyo, Inc., proposed for the treatment of adults with relapsed or refractory acute myeloid leukemia, which is FLT3-ITD positive, as detected by an FDA-approved test